Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premixed insulin versus Toujeo-based basal-plus regimen in elderly patients with type 2 diabetes mellitus
ACTRN12616001158459Phase 4Recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine and insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Western Sydney Local Health District. Primary endpoint: Percentage of time spent in hypoglycemia by CGM. Started Jan 2017; status: recruiting.
02
Drugs
insulin glargineinsulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12616001158459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001158459.